RAY B Share Price | RaySearch Laboratories AB Stock Analysis & Recommendation

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

73.66 k

Shareholding (Jun 2021)

FII

0.00%

Held by 1 FIIs

DII

100.0%

Held by 0 DIIs

Promoter

0.00%

Compare RaySearch Laboratories AB with Similar Stocks

Pagero Group AB Coinshares International Ltd.Tobii Dynavox AB

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

With ROE of 22.73%, it has a expensive valuation with a 9.49 Price to Book Value

The stock is trading at a discount compared to its peers' average historical valuations
Over the past year, while the stock has generated a return of -6.97%, its profits have risen by 27.6% ; the PEG ratio of the company is 1.5

Underperformed the market in the last 1 year

Mojo Parameters

Stock DNA

Industry

Software Products

Market cap

SEK 5,912 Million (Small Cap)

P/E

42.00

Industry P/E

Dividend Yield

1.35%

Debt Equity

-0.27

Return on Equity

23.84%

Price to Book

6.43

Revenue and Profits:

Net Sales:

305 Million

(Quarterly Results - Jun 2025)

Net Profit:

31 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

2246.59%

6 Months

3491.3%

1 Year

958.97%

2 Years

1558.63%

3 Years

839.92%

4 Years

945.57%

5 Years

1561.3%

RaySearch Laboratories AB for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

12.20%

EBIT Growth (5y)

35.45%

EBIT to Interest (avg)

16.94

Debt to EBITDA (avg)

1.05

Net Debt to Equity (avg)

-0.46

Sales to Capital Employed (avg)

1.23

Tax Ratio

22.43%

Dividend Payout Ratio

50.54%

Pledged Shares

Institutional Holding

0.00%

ROCE (avg)

18.78%

ROE (avg)

8.10%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

9.49

EV to EBIT

30.03

EV to EBITDA

21.84

EV to Capital Employed

14.79

EV to Sales

6.17

PEG Ratio

1.51

Dividend Yield

0.99%

ROCE (Latest)

49.25%

ROE (Latest)

22.73%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Mildly Bearish

Dow Theory

Mildly Bearish

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Jun 2021

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.0%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -4.39% vs 33.15% in Jun 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -49.84% vs 463.30% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "304.90",
          "val2": "318.90",
          "chgp": "-4.39%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "68.70",
          "val2": "80.00",
          "chgp": "-14.12%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "30.80",
          "val2": "61.40",
          "chgp": "-49.84%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "139.00%",
          "val2": "250.90%",
          "chgp": "-11.19%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 16.61% vs 21.17% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 149.39% vs 242.86% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,192.00",
          "val2": "1,022.20",
          "chgp": "16.61%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "546.40",
          "val2": "406.40",
          "chgp": "34.45%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "9.00",
          "val2": "9.70",
          "chgp": "-7.22%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "203.50",
          "val2": "81.60",
          "chgp": "149.39%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "207.20%",
          "val2": "117.60%",
          "chgp": "8.96%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

304.90

318.90

-4.39%

Operating Profit (PBDIT) excl Other Income

68.70

80.00

-14.12%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

30.80

61.40

-49.84%

Operating Profit Margin (Excl OI)

139.00%

250.90%

-11.19%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is -4.39% vs 33.15% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -49.84% vs 463.30% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

1,192.00

1,022.20

16.61%

Operating Profit (PBDIT) excl Other Income

546.40

406.40

34.45%

Interest

9.00

9.70

-7.22%

Exceptional Items

0.00

Consolidate Net Profit

203.50

81.60

149.39%

Operating Profit Margin (Excl OI)

207.20%

117.60%

8.96%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 16.61% vs 21.17% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 149.39% vs 242.86% in Dec 2023

All Annual Results

Company CV

About RaySearch Laboratories AB

RaySearch Laboratories AB

Software Products

RaySearch Laboratories publ AB is a Sweden-based medical technology company that develops software for radiation therapy of cancer. It markets and sells its products mainly in the United States and in Europe through license agreements with medical technology companies and scientific institutions. As of December 31, 2011, 15 of the Company’s products were launched, including the software platform ORBIT (optimization of radiation therapy beams by iterative technique), which is available in its main products, and is a non-clinical system which functions as a research and development environment. Additionally, its solutions include software for optimizing Intensity Modulated Radiation Therapy (IMRT) plans for photons, adaptive technology for IMRT treatments and software for proton treatments. The Company’s commercial partners are Philips, Nucletron and IBA Dosimetry, among others. In April 2014, it established a German subsidiary, RaySearch Germany GmbH.

Company Coordinates

Company Details

Sveavagen 44, Box 3297 , STOCKHOLM None : 103 65

Tel: 46 8 51053000

http://www.raysearchlabs.com

Registrar Details